Espinosa JLA, Cerda RS, Castillón BNK, Campos GRI, Maldonado HJC

Language: Spanish
References: 9
Page: 69-73
PDF size: 150.56 Kb.

ABSTRACT

Asthma is the most common chronic inflammatory disease worldwide. It has no preference at any age, gender, race, etc. Its severe form is defined according to the American Thoracic Society (ATS) as that which requires high doses of inhaled corticosteroids additionally a second controller or systemic steroids to avoid an exacerbation of the disease. Estimated prevalence of severe form goes to 2% to 10% of total asthmatic population. Now, we are running an observational study that analyses the prevalence of sever asthma in Unidad de Especialidades Médicas (SEDENA), according to ATS criteria and definitions in a period of time between January 1st, 2019 till now. From a total of 11,615 patients managed in Allergology and Immunology Service of this hospital; 2,565 (22%) were diagnosed with bronchial asthma. From these patients, 146 had criteria for severe asthma according to ATS which are 5.60% of asthmatic patients and 1.25% of total population. It is value to mention that the totality of patient is under biological therapy with monoclonal antibodies. As conclusion, according to the results gained through data and variables running, we could figure it out that asthma and severe asthma prevalence in this health institution matches global epidemiology and statistic.

REFERENCES

1. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018; 391 (10122): 783-800.

2. Barría PP, Holguin FF, Wenzel SS. Asma severa en adultos: enfoque diagnóstico y tratamiento. Rev Med Clin Condes. 2015; 26 (3): 267-275.

3. Larenas-Linnemann D, Salas-Hernández J, Vázquez-García JC, Ortiz-Aldana I, Fernández-Vega M, Del Río-Navarro BE et al. Guía Mexicana del Asma 2017. Rev Alerg Mex. 2017; 64 (Supl 1): s11-s128.

4. Backman H, Jansson SA, Stridsman C, Eriksson B, Hedman L, Eklund BM et al. Severe asthma-A population study perspective. Clin Exp Allergy. 2019; 49 (6): 819-828. doi: 10.1111/cea.13378.

5. Neffen H, Moraes F, Viana K, Di Boscio V, Levy G, Vieira C et al. Asthma severity in four countries of Latin America. BMC Pulm Med. 2019; 19 (1): 123. doi: 10.1186/s12890-019-0871-1.

6. Rehman A, Amin F, Sadeeqa S. Prevalence of asthma and its management: A review. J Pak Med Assoc. 2018; 68 (12): 1823-1827.

7. Del-Rio-Navarro B, Del Rio-Chivardi JM, Berber A, Sienra-Monge JJ, Rosas-Vargas MA, Baeza-Bacab M. Asthma prevalence in children living in north Mexico City and a comparison with other Latin American cities and world regions. Allergy Asthma Proc. 2006; 27 (4): 334-340. doi: 10.2500/aap.2006.27.2880.

8. Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020; 75 (5): 1023-1042. doi: 10.1111/all.14221.

9. McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care Med. 2019; 199 (4): 433-445. doi: 10.1164/rccm.201810-1944CI.